#Systemic Scleroderma Treatment Market Size
Explore tagged Tumblr posts
Visit Tumblr Blog
Explore Tumblr blogs with no restrictions, modern design and the best experience.
Last Seen Tumblr Blogs
Fun Fact
Total funding amounts to $125.3M.
Text
A Comprehensive Overview of Systemic Scleroderma Treatment Market Landscape
The global systemic scleroderma treatment market size is expected to reach USD 1.9 billion by 2027, according to a new study by Grand View Research Inc. The market is expected to expand at a CAGR of 4.0% from 2020 to 2027. The market is largely attributable to the strong presence of therapies used off-label that include small molecule therapies including branded, generics, and OTC drugs.
The mix of several indications and drug classes engenders a fragmented space with multiple players. Johnson and Johnson Services, Inc. dominated the market with a share of 23.7% in the year 2019. United Therapeutics Corporation is the second biggest service provider in the space with a significant share in 2019. The other players such as F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline plc, Novartis AG, and Pfizer Inc. also have a significant share of the global market.
The on-label treatment is in the development phase. Major players with therapies undergoing clinical development are divided into two sorts. There are some developing new compounds, whereas certain other established players are seen repurposing their drugs (currently approved for other indications) for scleroderma use. In September 2019, Boehringer Ingelheim GmbH announced the U.S. FDA approval of Ofev for the treatment of interstitial lung disease in patients with systemic sclerosis.
Supplemental indication approval is one of the most common strategies adopted by pharmaceutical players thriving in the space. There are several pharmaceutical companies adopting strategies that favor the pharmaceutical industry in offsetting high development costs.
Gather more insights about the market drivers, restrains and growth of the Systemic Scleroderma Treatment Market
Systemic Scleroderma Treatment Market Report Highlights
• The immunosuppressors segment held the largest revenue share in 2019, followed by prostacyclin analogues
• The high preference for immunosuppressants owing to the favorable reimbursement scenario associated with this drug class will support its dominant share in this space
• The U.S. held the majority of the revenue share in 2019. Expected label expansions and the expected launch of first-in-class therapies coupled with an evolving reimbursement landscape for orphan drugs are expected to support market growth
• Europe trails with a lower share as compared to the U.S. majorly due to higher use of generics and biosimilars for off-label treatment of scleroderma
Systemic Scleroderma Treatment Market Segmentation
Grand View Research has segmented the global systemic scleroderma treatment market based on drug class and region:
Systemic Scleroderma Treatment Drug Class Outlook (Revenue, USD Million, 2016 - 2027)
• Immunosuppressors
• Phosphodiesterase 5 inhibitors - PHA
• Endothelin Receptor Antagonists
• Prostacyclin Analogues
• Calcium Channel Blockers
• Others
Systemic Scleroderma Treatment Regional Outlook (Revenue, USD Million, 2016 - 2027)
• North America
o U.S.
o Canada
• Europe
o Germany
o U.K.
o France
o Italy
o Spain
• Asia Pacific
o China
o Japan
o India
o Australia
• Latin America
o Brazil
o Argentina
o Mexico
• MEA
o South Africa
o Saudi Arabia
o UAE
Order a free sample PDF of the Systemic Scleroderma Treatment Market Intelligence Study, published by Grand View Research.
#Systemic Scleroderma Treatment Market#Systemic Scleroderma Treatment Market Size#Systemic Scleroderma Treatment Market Share#Systemic Scleroderma Treatment Market Analysis#Systemic Scleroderma Treatment Market Growth
0 notes
Text
0 notes
Link
0 notes
Text
Scleroderma Therapeutics Market
Scleroderma Therapeutics Market Size, Share, Trends: F. Hoffmann-La Roche Ltd. Leads
Shift Towards Targeted Therapies and Biologics Reshapes Treatment Landscape
Market Overview:
The scleroderma therapeutics market is estimated to develop at a CAGR of XX% between 2024 and 2031, with market value rising from USD XX in 2024 to USD YY by 2031. North America now dominates the market, accounting for the vast majority of worldwide sales. Key metrics include rising scleroderma prevalence, increased research and development activity, and ongoing treatment innovation.
The market is steadily growing, owing to increased awareness of scleroderma, improved diagnostic procedures, and the development of novel medicines. Emerging economies are giving enormous development potential as healthcare infrastructure improves and healthcare expenditure increases.
DOWNLOAD FREE SAMPLE
Market Trends:
The scleroderma treatments market is seeing a dramatic shift towards the discovery and use of targeted medicines and biologics. The expanding understanding of scleroderma's complicated pathophysiology, as well as the need for more effective, personalised therapy choices, are driving this trend. Researchers and pharmaceutical companies are working to create medicines that target specific molecular pathways implicated in disease progression, such as fibrosis, inflammation, and vascular dysfunction.
For example, many monoclonal antibodies and small molecule inhibitors targeting critical cytokines and growth factors involved in scleroderma pathogenesis are in various phases of clinical development. Furthermore, there is considerable interest in repurposing current biologics used in other autoimmune disorders to treat scleroderma. This trend towards focused therapy not only promises more effective treatments, but it may also reduce the negative effects associated with broader immunosuppression. The use of precision medicine approaches in scleroderma care is likely to continue to shape the market landscape, encouraging innovation and possibly improving patient outcomes.
Market Segmentation:
Immunosuppressants have emerged as the dominant sector in the scleroderma therapies market, owing to their crucial role in treating the disease's autoimmune and inflammatory components. This segment's dominance is based on the long-standing use of immunosuppressive medicines to treat various scleroderma symptoms, notably rapidly progressing systemic sclerosis. Immunosuppressants function by modifying the immune response, which is critical in a condition characterised by immunological dysregulation and fibrosis.
The global market for immunosuppressors in scleroderma treatment was worth roughly $YY million in 2023, with forecasts predicting consistent expansion in the next few years. The rising usage of both classic immunosuppressants such as methotrexate and mycophenolate mofetil, as well as novel biologics having immunosuppressive qualities, is driving this growth. The immunosuppressant market is also benefiting from continuing research into more tailored immunomodulatory techniques, which promise greater efficacy with fewer adverse effects.
Market Key Players:
F. Hoffmann-La Roche Ltd.
Boehringer Ingelheim International GmbH
Johnson & Johnson Services, Inc.
Bristol-Myers Squibb Company
Bayer AG
Sanofi
Contact Us:
Name: Hari Krishna
Email us: [email protected]
Website: https://aurorawaveintellects.com/
0 notes
Text
The global Raynaud’s disease therapeutics market is expected to grow from an estimated USD 12,995 million in 2024 to approximately USD 23,141.82 million by 2032, with a compound annual growth rate (CAGR) of 7.48% over the forecast period.Raynaud’s disease, also known as Raynaud’s phenomenon, is a rare condition that affects blood flow to specific areas of the body—most commonly the fingers and toes. Characterized by episodes of vasospasm that cause the affected areas to turn white or blue, Raynaud’s can be primary (occurring independently) or secondary (associated with underlying conditions like scleroderma or lupus). The disease's complex nature poses significant challenges in both diagnosis and treatment, creating a dynamic and evolving market for therapeutics.
Browse the full report at https://www.credenceresearch.com/report/raynauds-disease-therapeutics-market
Market Overview
The global Raynaud’s disease therapeutics market has witnessed steady growth over the years, driven by increasing disease awareness, improved diagnostic techniques, and advances in pharmacological therapies. According to recent estimates, the market is poised to expand significantly as healthcare infrastructure improves and research into autoimmune and vascular conditions intensifies.
Factors driving market growth include:
Rising Prevalence: Although considered a rare disease, the prevalence of Raynaud’s is increasing, especially in regions with cold climates where the condition is exacerbated.
Advancements in Research: New insights into the pathophysiology of Raynaud’s, including its links to autoimmune disorders, are fostering the development of targeted therapies.
Increased Awareness and Diagnosis: Campaigns aimed at educating patients and healthcare professionals about early symptoms have led to more timely interventions.
Current Therapeutic Options
Raynaud’s disease management primarily focuses on reducing the frequency and severity of vasospastic episodes and preventing tissue damage. The treatment options include pharmacological and non-pharmacological approaches:
Calcium Channel Blockers (CCBs): Drugs like nifedipine are first-line treatments, effectively dilating blood vessels to improve blood flow.
Vasodilators: Agents such as nitroglycerin ointments are often used for localized treatment.
Endothelin Receptor Antagonists: These are emerging as promising options, particularly for secondary Raynaud’s associated with systemic sclerosis.
Lifestyle Modifications: Avoidance of triggers such as smoking and cold exposure remains a cornerstone of management.
Despite the availability of these treatments, significant unmet needs persist. Many patients report suboptimal outcomes with current therapies, necessitating the exploration of innovative solutions.
Emerging Therapies and Innovations
The Raynaud’s disease therapeutics market is seeing a wave of innovation, with several novel approaches in the pipeline:
Botulinum Toxin Injections: Studies have shown that Botox can alleviate severe symptoms in some cases by inhibiting nerve-induced vasospasm.
Advanced Vasodilators: New classes of drugs, including prostacyclin analogs, are being tested for their efficacy in severe cases.
Gene and Cell Therapies: Though still in experimental stages, regenerative approaches may hold promise for repairing vascular damage.
Digital Health Solutions: Wearable devices and apps designed to monitor and manage Raynaud’s symptoms are gaining traction, offering patients greater control over their condition.
Challenges and Future Outlook
The Raynaud’s disease therapeutics market faces several challenges:
Limited Awareness: In many regions, particularly in developing countries, the condition remains underdiagnosed.
High Treatment Costs: Advanced therapies are often expensive, limiting accessibility.
Regulatory Hurdles: The development of new drugs for rare conditions like Raynaud’s is often impeded by stringent approval processes.
Looking ahead, the market’s future appears promising. Collaborative efforts between governments, research organizations, and pharmaceutical companies are essential to overcoming existing barriers. Expanding access to affordable treatments, increasing awareness, and fostering innovation will be critical to addressing the unmet needs of Raynaud’s disease patients.
Key Player Analysis:
Bayer AG
Apricus Biosciences, Inc.
GlaxoSmithKline plc.
Teva Pharmaceutical Industries Ltd.
Pfizer Inc.
Covis Pharmaceuticals, Inc.
Allergan plc
Zydus Pharma USA, Inc.
Vicore Pharma
Actelion Pharmaceuticals Ltd.
Segmentations:
By Product
Acetylcysteine
Alprostadil
Els-140
Neovasculgen
Nitroglycerin
Others
By Application
Hospital
Clinic
Others
By Geography
North America
U.S.
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Rest of Europe
Asia Pacific
China
Japan
India
South Korea
South-east Asia
Rest of Asia Pacific
Latin America
Brazil
Argentina
Rest of Latin America
Middle East & Africa
GCC Countries
South Africa
Rest of the Middle East and Africa
Browse the full report at https://www.credenceresearch.com/report/raynauds-disease-therapeutics-market
About Us:
Credence Research is committed to employee well-being and productivity. Following the COVID-19 pandemic, we have implemented a permanent work-from-home policy for all employees.
Contact:
Credence Research
Please contact us at +91 6232 49 3207
Email: [email protected]
0 notes
Text
Dry eye syndrome market size is projected to grow at a compound annual growth rate of 5.9% over the forecast period of 2021 to 2028. Data Bridge Market Research report on dry eye syndrome market provides analysis and insights regarding the various factors expected to be prevalent throughout the forecasted period while providing their impacts on the market’s growth.
Dry eye syndrome (also referred as keratoconjunctivitis sicca or KCS), is a multifactorial disease that occurs due to the lack of lubrication or moisture on the surface of the infected person’s eyes, which might make possible damage to the ocular surface. It is a commonly occurring disease which can affect almost anyone, which can be caused due to excessive computer uses, allergies, LASIK eye surgery, aging, menopause, smoking or hormone replacement therapy among others. Its symptoms include watery eyes, photophobia, eye redness, sore eyes, stinging burning, eye fatigue, blurred vision and scratchy sensation in eyes.
The rising geriatric population and rapid rise in prevalence of diseases such as Sjogren’s syndrome, diabetes, thyroid disorders, scleroderma, rheumatoid arthritis and lupus among others also result in dry eyes which is expected to accelerate the market growth. Additionally, rising diagnostic rates, increasing awareness levels regarding dry eye syndrome and presence of better and advanced treatment options will further carve the way for the growth of the market. However, the factors such as high cost of specialty dry eye products and availability of alternative therapies across the globe is projected to restrain the market growth rate. The complex reimbursement scenario also hampers the market’s growth rate in the forecast period of 2021 to 2028.
In addition, the increasing investment in the research and development of treatment options associated with this disease are likely to create various new opportunities that will impact this dry eye syndrome market growth in the forecast period of 2021 to 2028.The lockdown due to COVID-19 pandemic led to disruption of healthcare systems, which is estimated to challenge the market’s growth.
0 notes
Text
Systemic scleroderma treatment Market Growth Factors, Latest Trend And Regional Analysis Of Leading Players By 2027
The global systemic scleroderma treatment market expected to reach USD 2.09 billion by 2028 according to a new study by Polaris Market Research. The report “Systemic Scleroderma Treatment Market Share, Size, Trends, Industry Analysis Report, By Drug Class (Immunosuppressors, Phosphodiesterase 5 inhibitors-PHA, Endothelin Receptor Antagonists, Prostacyclin Analogues, Calcium Channel Blockers, Others); By Regions; Segment Forecast, 2021 – 2028”
The global market for systemic scleroderma treatment is anticipated to grow due to presence of innovative small molecule therapies, significant government backed funding, and increasing clinical trials for the concerned diseases. Moreover, the presence industry-academia collaborations in the developed countries are favoring the systemic scleroderma treatment industry growth.
The global market for systemic scleroderma treatment is fragmented based on drug class and region. The drug class market segment has been bifurcated into immuno-suppressors, phosphodiesterase 5 inhibitors-PHA, endothelin receptor antagonists, prostacyclin analogues, calcium channel blockers, and others. The systemic scleroderma treatment industry region segment has been bifurcated into North America, Europe, Asia Pacific, Latin America, Middle East & Africa.
Request Sample Copy at : https://www.polarismarketresearch.com/industry-analysis/systemic-scleroderma-treatment-market/request-for-sample
Segment Highlights
Immunosuppressors market segment accounted for over 60% of the overall market revenue share in 2020 and is expected to continue its dominance in systemic scleroderma treatment industry over the forecast period owing to higher efficiency and comparatively improved results.
North America systemic scleroderma treatment industry is dominating the global market for systemic scleroderma treatment, holding over 40% of the market share throughout forecast period. Favorable reimbursement scenario and strong drug pipeline favoring the systemic scleroderma treatment industry growth.
The market players including Roche Ltd.; United Therapeutics; Boehringer Ingelheim International GmbH together held a significant market share of global market for systemic scleroderma treatment in year 2020.
List of Key Players of Systemic Scleroderma Treatment Industry
Hoffmann La Roche Ltd.
Johnson & Johnson Services, Inc.
United Therapeutics
Boehringer Ingelheim International GmbH
GlaxoSmithKline plc
Pfizer, Inc.
Eli Lilly and Company
Bayer AG
Mylan N.V.
Teva Pharmaceutical Industries Ltd.
Others
To get Incredible Discounts on this Premium Report, Click At : https://www.polarismarketresearch.com/industry-analysis/systemic-scleroderma-treatment-market/request-for-discount-pricing
Polaris Market Research has segmented systemic scleroderma treatment market report on the basis of drug class and region:
Systemic Scleroderma Treatment, Drug Class Outlook (Revenue – USD Million, 2016 – 2028)
Immunosuppressors
Phosphodiesterase 5 inhibitors – PHA
Endothelin Receptor Antagonists
Prostacyclin Analogues
Calcium Channel Blockers
Others
Systemic Scleroderma Treatment, Regional Outlook (Revenue – USD Million, 2016 – 2028)
North America
Europe
Asia Pacific
Central & South America
Middle East & Africa
U.S.
Canada
France
Germany
UK
Italy
Spain
Netherlands
Austria
China
India
Japan
Malaysia
South Korea
Indonesia
Mexico
Brazil
Argentina
UAE
Saudi Arabia
Israel
South Africa
Read More: https://www.medgadget.com/2021/02/systemic-scleroderma-treatment-market-2-09-billion-by-2028-cagr-4-1-polaris-market-research.html
0 notes
Text
Systemic Scleroderma Treatment Market Insight And Growth By Top Companies 2028
New York, NY 20 May 2021: The global systemic scleroderma treatment market expected to reach USD 2.09 billion by 2028 according to a new study by Polaris Market Research. The report “Systemic Scleroderma Treatment Market Share, Size, Trends, Industry Analysis Report, By Drug Class (Immunosuppressors, Phosphodiesterase 5 inhibitors-PHA, Endothelin Receptor Antagonists, Prostacyclin Analogues, Calcium Channel Blockers, Others); By Regions; Segment Forecast, 2021 – 2028”
The global market for systemic scleroderma treatment is anticipated to grow due to presence of innovative small molecule therapies, significant government backed funding, and increasing clinical trials for the concerned diseases. Moreover, the presence industry-academia collaborations in the developed countries are favoring the systemic scleroderma treatment industry growth.
The global market for systemic scleroderma treatment is fragmented based on drug class and region. The drug class market segment has been bifurcated into immuno-suppressors, phosphodiesterase 5 inhibitors-PHA, endothelin receptor antagonists, prostacyclin analogues, calcium channel blockers, and others. The systemic scleroderma treatment industry region segment has been bifurcated into North America, Europe, Asia Pacific, Latin America, Middle East & Africa.
Request For Sample Copy @ https://www.polarismarketresearch.com/industry-analysis/systemic-scleroderma-treatment-market/request-for-sample
Segment Highlights
Immunosuppressors market segment accounted for over 60% of the overall market revenue share in 2020 and is expected to continue its dominance in systemic scleroderma treatment industry over the forecast period owing to higher efficiency and comparatively improved results.
North America systemic scleroderma treatment industry is dominating the global market for systemic scleroderma treatment, holding over 40% of the market share throughout forecast period. Favorable reimbursement scenario and strong drug pipeline favoring the systemic scleroderma treatment industry growth.
The market players including Roche Ltd.; United Therapeutics; Boehringer Ingelheim International GmbH together held a significant market share of global market for systemic scleroderma treatment in year 2020.
List of Key Players of Systemic Scleroderma Treatment Industry
Hoffmann La Roche Ltd.
Johnson & Johnson Services, Inc.
United Therapeutics
Boehringer Ingelheim International GmbH
GlaxoSmithKline plc
Pfizer, Inc.
Eli Lilly and Company
Bayer AG
Mylan N.V.
Teva Pharmaceutical Industries Ltd.
Others
Polaris Market Research has segmented systemic scleroderma treatment market report on the basis of drug class and region:
Systemic Scleroderma Treatment, Drug Class Outlook (Revenue – USD Million, 2016 – 2028)
Immunosuppressors
Phosphodiesterase 5 inhibitors – PHA
Endothelin Receptor Antagonists
Prostacyclin Analogues
Calcium Channel Blockers
Others
To get Incredible Discounts on this Premium Report, Click At : https://www.polarismarketresearch.com/industry-analysis/systemic-scleroderma-treatment-market/request-for-discount-pricing
About Polaris Market Research
Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for our clientele spread across different enterprises.
Contact Us:
Polaris Market Research
Phone: 1–646–568–9980
Email: [email protected]
Web: http://www.polarismarketresearch.com
0 notes
Text
Complete report about Scleroderma (Systemic Sclerosis) Treatment Market to 2028
Scleroderma (systemic sclerosis) treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the scleroderma (systemic sclerosis) treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you make an informed market decision to achieve market growth.
Download Sample Report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-scleroderma-systemic-sclerosis-treatment-market
Market Analysis and Insights
The scleroderma (systemic sclerosis) treatment market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market to will grow at a CAGR of 6.2% in the above-mentioned forecast period.
Systemic sclerosis is a type of chronic autoimmune disorder illustrated by skin hardening, irritation in multiple organs and the most common symptom is the thickening of the skin in this disease. The disease's accurate cause is unidentified, but it is known to have an over-production of collagen in the body.
Get TOC @ https://www.databridgemarketresearch.com/toc/?dbmr=global-scleroderma-systemic-sclerosis-treatment-market
You will get an answer for the following questions like
What CGAR Scleroderma (systemic sclerosis) treatment market?
What is the estimated valuation for the Scleroderma (systemic sclerosis) treatment market?
Who are the key players of the Scleroderma (systemic sclerosis) treatment market?
What are the technology segments of the Scleroderma (systemic sclerosis) treatment market?
The Key players included in the Global Scleroderma (systemic sclerosis) treatment market report
Actelion Pharmaceuticals Ltd
F. Hoffmann-La Roche Ltd
Bristol-Myers Squibb Company
BoehringerIngelheim International GmbH
Allergan
GlaxoSmithKline plc
Biogen
Novartis AG
The countries covered in the report are
U.S
Canada
Mexico
Germany
Italy
U.K.
France
Spain
Netherland
Belgium
View full report @ https://www.databridgemarketresearch.com/reports/global-scleroderma-systemic-sclerosis-treatment-market
Customization Available: Global Scleroderma (Systemic Sclerosis) Treatment Market
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market, and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.
Browse related reports @
Portable Fire Extinguisher Market
Shampoo Market
Shisha Tobacco Market
Smart Doorbell Market
Smart Kitchen Appliances Market
About Us:
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with an unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market
Contact:
Data Bridge Market Research
Tel: +1-888-387-2818
Email: [email protected]
0 notes
Link
0 notes
Text
Antinuclear Antibody Test Market Competitive Landscape, Research Methodology, Business Opportunities, Statistics and Industry Analysis Report by 2028
Reports and Data has recently added a new research report titled ‘Global Antinuclear Antibody Test Market Forecast to 2028’ to its wide database that offers extensive information about the Antinuclear Antibody Test market with regards to market size, market share, revenue growth, global and regional reach, and product portfolio offered by the market. The report discusses in detail the business landscape and highlights changes in the market dynamics as a result of pandemic, disease outbreak, and other scenarios. The industry has also observed significant increase in sales owing to the COVID-19 outbreak and the report assesses the effect of pandemic on the market position of the key participants in the market. The report also offers key insights into research and development activities, investment & funding, financial standing, drug discovery, development and pipeline, and product offerings that are influencing the industry growth.
The report focuses on current and emerging trends in the healthcare industry such as incorporation of Machine Learning and Internet of Things to enhance efficiency of medical products. Top companies in the market are focusing on R&D activities to expand their product offerings and cater to unmet medical needs.
The pharmaceutical and healthcare industry has observed significant igrowth over the recent past owing to emergence of new diseases, infections, and outbreak of COVID-19 illness. The global Antinuclear Antibody Test market size reached a significantly robust value in 2020 and is expected to register a notable CAGR over the forecast period.
Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/4080
Market Dynamics:
Continuous investments made by the pharmaceutical and outsourcing firms to expand their manufacturing facilities have reinforced Antinuclear Antibody Test market trends. The advances in the field of personalized medicines has opened up numerous possibilities to target different health disorders and allowed the development of patient-centric models. This progress has resulted in a shift from large batches to smaller batches for the development of complex medicines and autologous patient-centric treatments. Increasing focus of the manufacturers to redesign their supply chain in order to better align with the patient-centric health care system is expected to bolster pharma and healthcare market growth.
Going forward, faster economic growth, technological developments and the increasing prevalence of diseases due to busy and sedentary lifestyles will further foster market size. Factors that could hinder the growth of this market in the future are arising from increasing awareness of alternative therapies & natural remedies, and stringent government regulations for new drug approvals.
Competitive Outlook:
Rise in new product launches and initiatives by the market players to address diseases of the patients is contributing to the pharma and healthcare industry revenue. Market-trend-based strategies for the healthcare market include increasing the adoption of bundled payments, using digital tools, increasing collaborations across industries and companies, focusing on the development of new medicines, and adopting hybrid imaging technology.
The competitive outlook section of the report discusses in detail the company overview, product and services portfolio, business expansion plans, production and manufacturing capacity, financial standing, and global market position. It further sheds light on the recent mergers and acquisitions, collaborations, partnerships, corporate and government deals, agreements, and product launches.
Top companies operating in the market and profiled in the report include:
Alere Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), ERBA Diagnostics, Inc. (U.S.), Trinity Biotech plc (Ireland), Thermo Fisher Scientific, Inc. (U.S.), Antibodies, Inc. (U.S.), EUROIMMUN AG (Germany), Immuno Concepts (U.S.), Inova Diagnostics (U.S.), and Zeus Scientific, Inc. (U.S.)
To know more about the report @ https://www.reportsanddata.com/press-release/global-antinuclear-antibody-test-market
Further, the report segments the Antinuclear Antibody Test market on the basis of product types, applications, regions, and others. The report offers insights into key factors influencing the revenue growth of the segment and provides information about lucrative investment opportunities to stakeholders, investors, and clients.
Antinuclear Antibody Test Market Segmentation:
Product Outlook (Revenue, USD Billion, 2018-2028)
Reagents & Assay Kits
Systems
Software & Services
Technique Outlook (Revenue, USD Billion, 2018-2028)
ELISA
Immunofluorescence Assay
Multiplex Assay
Application Outlook (Revenue, USD Billion, 2018-2028)
Rheumatoid Arthritis
Systemic Lupus Erythematosus
Sjogren’s Syndrome
Scleroderma
Others
End-use Outlook (Revenue, USD Billion, 2018-2028)
Hospitals
Clinical Laboratories
Physician Office Laboratories
Others
Regional Analysis covers:
North America
Europe
Asia Pacific
Latin America
Middle East & Africa
U.S.
Canada
Mexico
Germany
Italy
U.K.
Rest of EU
India
China
Japan
South Korea
Rest of APAC
Brazil
Argentina
Rest of Latin America
Saudi Arabia
South Africa
A.E
Rest of MEA
Request a customization of the report @ https://www.reportsanddata.com/request-customization-form/4080
Thank you for reading our report. To gain more insight on the market, please contact Reports and Data for an Analyst Brief. Our team will help you take an informed market decision to achieve business growth.
Browse More Details:
Infrastructure as a Service (IaaS) Market Share
Osteosynthesis Devices Market Growth
0 notes
Text
Asia-Pacific Anti-Nuclear Antibody Test Market Headed for Growth and Global Expansion by 2027
Market Analysis and Insights: Asia-Pacific Anti-Nuclear Antibody Test Market
Asia-Pacific Anti-Nuclear Antibody Test Market, By Product (Assay Kits & Reagents, Systems, Software), Test (Indirect Immunofluorescence, ELISA, Multiplex Testing), Disease (Systemic Lupus Erythematosus, Sjögren’s Syndrome, Rheumatoid Arthritis, Scleroderma, Polymyositis, Others), End-User (Hospitals, Clinics, Physician Office Laboratories, Others), Country (Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia- Pacific) Industry Trends and Forecast to 2027
Download Exclusive Sample PDF at: https://www.databridgemarketresearch.com/request-a-sample/?dbmr=asia-pacific-anti-nuclear-antibody-test-market
Anti-nuclear antibody test market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to account to USD 598.75 million by 2027 growing at a CAGR of 12.45 % in the above-mentioned forecast period. The growing incidence of autoimmune diseases will help in driving the growth of the anti-nuclear antibody test market.
The increasing population and rise in healthcare expenditure such as medical insurance and government initiatives to cover healthcare protection and increasing research and development activities in the medical field is likely to accelerate the growth of the anti-nuclear antibody test market in the forecast period of 2020-2027. On the other hand, rising healthcare expenditure emerging markets and laboratory automation is further going to boost various opportunities that will lead to the growth of the anti-nuclear antibody test market in the above mentioned forecast period.
Strict regulation for product approval is likely to hamper the growth of the anti-nuclear antibody test market in the above mentioned forecast period. Lack of skilled labour and technician is going to be a challenge for the market.
This anti-nuclear antibody test market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographical expansions, technological innovations in the market. To gain more info on Anti-Nuclear Antibody Test market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Asia-Pacific Anti-Nuclear Antibody Test Market Scope and Market Size
Anti-nuclear antibody test market is segmented on the basis of product, test, disease and end-user. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.
Based on product, the anti-nuclear antibody test market is segmented into assay kits & reagents, systems, software.
Anti-nuclear antibody test market has also been segmented based on the test into indirect immunofluorescence, ELISA, and multiplex testing
On the basis of disease, the anti-nuclear antibody test market is segmented into systemic lupus erythematosus, sjögren’s syndrome, rheumatoid arthritis, scleroderma, polymyositis, others
The anti-nuclear antibody test market is segmented on the basis of end-user into hospitals, clinics, physician office laboratories, others. Hospitals are further sub segmented into small, mid-sized and large hospitals
Have Any Query? Ask Our Expert @ https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=asia-pacific-anti-nuclear-antibody-test-market
Anti-Nuclear Antibody Test Market Country Level Analysis
Anti-nuclear antibody test market is analysed and market size insights and trends are provided by country, product, test, disease and end-user as referenced above.
The countries covered in the anti-nuclear antibody test market report are Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia- Pacific.
Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2020 to 2027 due to high prevalence of autoimmune diseases in countries such as India and China.
The country section of the anti-nuclear antibody test market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Request for TOC @-https://www.databridgemarketresearch.com/toc/?dbmr=asia-pacific-anti-nuclear-antibody-test-market
Healthcare Infrastructure growth Installed base and New Technology Penetration
Anti-nuclear antibody test market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment’s, installed base of different kind of products for anti-nuclear antibody test market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the anti-nuclear antibody test market. The data is available for historic period 2010 to 2018.
Competitive Landscape and Anti-Nuclear Antibody Test Market Share Analysis
Anti-nuclear antibody test market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Asia-Pacific presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to anti-nuclear antibody test market.
The major players covered in the anti-nuclear antibody test market report are Thermo Fisher Scientific, Abbott., Bio-Rad Laboratories, Inc., Trinity Biotech Ireland, Erba Diagnostics, Antibodies Incorporated, PerkinElmer, Inc., Immuno Concepts, Inova Diagnostics, Inc., ZEUS Scientific, Inc., among other domestic and Asia-Pacific players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
Customization Available: Asia-Pacific Anti-Nuclear Antibody Test Market
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customised to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.
Browse more related report to know about market analysis
Asia-Pacific Anti-Nuclear Antibody Test Market
Asia-Pacific Rx Dermatology Topical Drug Delivery Market
Europe Anticoagulation Therapy Market
Europe Dry Eye Syndrome Treatment Market
Ameloblastic Carcinoma Market
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market
Contact: Data Bridge Market Research
Tel: +1-888-387-2818
Email: [email protected]
0 notes
Text
Global Anti-nuclear Antibody (ANA) Testing Market information, by type (immunofluorescence, enzymelinked, immunosorbent assay (ELISA) and others), by application (Rheumatoid arthritis, Systemic lupus erythematosus (SLE), Polymyositis, Scleroderma, Sjögren's syndrome, and others), by End User (Hospitals and clinics, research laboratories, and others) - Forecast to 2023
Anti-nuclear Antibody (ANA) Test is used to detect antinuclear antibodies in blood. Immune system makes antibodies to fight with various infections. Antinuclear antibodies often attack on own tissues. ANA test helps to determine autoimmune diseases like rheumatoid arthritis and lupus. Increasing technological advancements, adoption of new techniques and increasing prevalence of various autoimmune diseases are driving the growth for global anti-nuclear antibody (ANA) testing market. Major brands are investing money in R&D to develop more advanced product for the market that is another key driver for the market.
The Global Anti-nuclear Antibody (ANA) testing market is growing at the CAGR of ~9.6% during the forecast period and expected to reach US$ 1300.6 million by 2023.
Key Players for Global Anti-nuclear Antibody (ANA) Testing Market:
Some of the key players in this market are: Abcam plc. (US), Alere (US), Antibodies Inc.(US), Bio-Rad Laboratories, Inc. (US), Erba Diagnostics (US), Indur Services, Inc. (US), MBL INTERNATIONAL (US), Merck KGaA (Germany), Trinity Biotech (Republic of Ireland)
Intended Audience
Anti-nuclear Antibody (ANA) Test products manufacturers
Anti-nuclear Antibody (ANA) Test products and services providers
Medical Research laboratories
Research and Development (R&D) Companies
Market Research and Consulting Service Providers
Potential Investors
Market Segments:
Global Anti-nuclear Antibody (ANA) Testing Market has been segmented on the basis of type which comprise immunofluorescence (Primary or direct and Secondary or indirect), enzymelinked, immunosorbent assay (ELISA) (Direct ELISA, Indirect ELISA, Sandwich ELISA, Competition/Inhibition ELISA), and others. On the basis of application, it segmented into Rheumatoid arthritis (Seropositive, Seronegative), Systemic lupus erythematosus (SLE) (Discoid lupus erythematosus, Subacute cutaneous lupus erythematosus, Neonatal lupus), Polymyositis, Scleroderma (localized scleroderma, systemic scleroderma), Sjögren's syndrome (Primary, secondary) , and others. On the basis of end user, it segmented into Hospitals and clinics, research laboratories, and others.
FIGURE 1 GLOBAL ANTI-NUCLEAR ANTIBODY (ANA) TESTING MARKET SHARE, BY APPLICATION (%)
Study objectives of Global Anti-nuclear Antibody (ANA) Testing Market:
To provide detailed analysis of the Global Anti-nuclear Antibody (ANA) Testing market structure with historical and forecast revenue for the next 7 years of the various segments and sub-segments of the Anti-nuclear Antibody (ANA) Testing Market
To provide insights about the key drivers, restraints, opportunities and challenges that affecting the growth of the Anti-nuclear Antibody (ANA) Testing market
To provide analysis of the market with respect to four main geographies and their countries- Americas, Europe, Asia-Pacific, and Middle East & Africa.
To provide detail analysis of the market that segmented on the basis of type, by application, by end user, and its sub-segments.
To provide detail analysis of global Anti-nuclear Antibody (ANA) testing market mainly based on value chain analysis, Porter’s five forces, Price analysis, and Supply Chain analysis etc.
To provide detail country level analysis of the market with respect to the current market size and future prospective
To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the Global Anti-nuclear Antibody (ANA) Testing Market
To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the Anti-nuclear Antibody (ANA) Testing market
Regional Analysis of Global Anti-nuclear Antibody (ANA) Testing Market:
Considering the global scenario of the market, North America is largest market for Anti-nuclear Antibody (ANA) Testing, in North America region US hold largest market share while European market is second largest, and especially the growth rate is higher in west European countries. On the other hand, Asia-Pacific (APAC) is fastest growing market and expected to grow significantly during the forecast period. Middle East and Africa (ME&A) is likely to have a limited growth in the market due to less awareness of devices and treatment.
Global Anti-nuclear Antibody (ANA) Testing Market, by Region
US
Canada
Germany
France
Italy
Spain
UK
Rest of Western Europe
Japan
China
India
Australia
South Korea
Rest of Asia-Pacific
Middle East
Africa
Research Methodology:
Sources: Directorate of Industries, Annual report, White paper, Company Presentation
The report for Global Anti-nuclear Antibody (ANA) Testing Market of Market Research Future comprises extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions.
0 notes
Text
Systemic scleroderma treatment Market Growth Factors, Latest Trend And Regional Analysis Of Leading Players By 2027
Systemic scleroderma treatment Market Growth Factors, Latest Trend And Regional Analysis Of Leading Players By 2027
The global systemic scleroderma treatment market expected to reach USD 2.09 billion by 2028 according to a new study by Polaris Market Research. The report “Systemic Scleroderma Treatment Market Share, Size, Trends, Industry Analysis Report, By Drug Class (Immunosuppressors, Phosphodiesterase 5 inhibitors-PHA, Endothelin Receptor Antagonists, Prostacyclin Analogues, Calcium Channel Blockers,…
View On WordPress
0 notes
Text
Raynaud’s Disease Market Size & Share, Market Report 2030
Raynaud’s phenomenon (RP) is caused by episodic vasospasm and ischemia of the extremities in response to cold or emotional stimuli, which result in a characteristic triphasic color change in extremities usually fingers or toes from white, to blue, to red. RP is usually seen in distal digits but may also involve nose, ears and tongue.
Raynaud’s phenomenon may be distinguished as primary, which is the occurrence of the vasospasm alone, with no association with another illness and Secondary caused by an underlying condition like autoimmune disorders such as rheumatoid arthritis, scleroderma, systemic lupus erythematosus and others.
DelveInsight's "Raynaud’s Disease - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Raynaud’s Disease, historical and forecasted epidemiology as well as the Raynaud’s Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Raynaud’s Disease market report provides current treatment practices, emerging drugs, Raynaud’s Disease market share of the individual therapies, current and forecasted Raynaud’s Disease market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Raynaud’s Disease treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Geography Covered
· The United States
· EU5 (Germany, France, Italy, Spain, and the United Kingdom)
· Japan
Request for sample pages: https://www.delveinsight.com/sample-request/raynauds-disease-market
Raynaud’s Disease Disease Understanding and Treatment Algorithm
The DelveInsight Raynaud’s Disease market report gives a thorough understanding of the Raynaud’s Disease by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.
Raynaud’s Disease Epidemiology
The Raynaud’s Disease epidemiology division provide insights about historical and current Raynaud’s Disease patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Key Findings:
· The prevalence of Raynaud’s phenomenon (RP) in most studies of the general population is between 3 and 5 %. Primary RP accounts for 80–90 % of cases.
· According to the review of literature, the prevalence of primary Raynaud’s varies among different populations; from 4.9–20.1% in women to 3.8–13.5% in men whereas the frequency of secondary Raynaud’s depends on the underlying disorder.
· Primary Raynaud’s affects more women than men, generally��under the age of 30 and secondary Raynaud’s age at onset is > 30.
Raynaud’s Disease Drug Chapters
The dedicated research with advances in the understanding of Raynaud’s phenomenon, laid the footsteps of various therapies with the key role of global players such as Seelos Therapeutics, Bayer, Allergan and others in developing potential therapies for Raynaud’s phenomenon at the global level. Launch of emerging therapies, such as RayVa (Seelos Therapeutics), and others are expected to significantly impact the treatment scenario of Raynaud’s phenomenon in the upcoming years 2019-2028.
Drug chapter segment of the Raynaud’s Disease report encloses the detailed analysis of Raynaud’s Disease marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Raynaud’s Disease clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Download sample pages: https://www.delveinsight.com/sample-request/raynauds-disease-market
Raynaud’s Disease Market Outlook
The first step in managing Raynaud’s phenomenon in primary care is lifestyle modification. Such advice can be given to patients while awaiting investigations and referral to secondary care if an underlying cause is suspected. Most people with primary Raynaud’s phenomenon respond well to lifestyle measures and need no further treatment. Patients with secondary Raynaud’s phenomenon require treatment of the underlying disorder.
Drug therapy is recommended in patients with secondary Raynaud phenomenon who have severe attacks or if there is evidence of tissue damage such as digital ulcerations. Treating the underlying disease process is most important (e.g., thyroid replacement if there is hypothyroid). The most common medications used for Raynaud’s phenomenon are calcium channel blockers such as amlodipine, nifedipine, felodipine, as well as angiotensin-receptor blockers. These medications act by increasing blood flow to the fingers and toes. For patients with more severe symptoms or who have developed complications such as ulcers on the fingertips, other medications can be used, including sildenafil or prostacyclins. Sometimes, patients are also prescribed other medications that can help improve symptoms, including topical creams, selective-serotonin-reuptake inhibitors (SSRIs), or cholesterol-lowering (statin) medications.
The Raynaud’s Disease market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Raynaud’s Disease market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
According to DelveInsight, Raynaud’s Disease market in 7MM is expected to change in the study period 2017-2030.
Click here to get free sample pages: https://www.delveinsight.com/sample-request/raynauds-disease-market
0 notes